Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients-Reference-Cited by-同舟云学术

Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients

Published:2020-04-07 Issue:16 Volume:71 Page:2227-2229
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Perinel Sophie¹²,Launay Manon³,Botelho-Nevers Élisabeth⁴,Diconne Éric¹,Louf-Durier Aurore¹,Lachand Raphaël¹,Murgier Martin¹,Page Dominique¹,Vermesch Régine¹,Thierry Guillaume¹,Delavenne Xavier²³^ORCID

Affiliation:

1. Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire (CHU) de Saint-Etienne, France

2. Institut National de la Santé et de la Recherche Médicale U1059, Dysfonctions Vasculaires et de L’Hémostase, Université de Lyon, Saint-Etienne, France

3. Laboratoire de Pharmacologie, Toxicologie, Gaz du Sang, CHU de Saint-Etienne, France

4. Infectious Diseases Department, CHU de Saint-Etienne, France

Abstract

Abstract Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. However, all ongoing clinical trials with HCQ use different dosing regimens, resulting in various concentrations. Pharmacokinetic studies are therefore needed to define the optimal dosing regimen.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa394/33462086/ciaa394.pdf

Reference9 articles.

1. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro;Wang;Cell Res,2020

2. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis;Carmichael;Ther Drug Monit,2003

3. Bioavailability of hydroxychloroquine tablets in healthy volunteers;Tett;Br J Clin Pharmacol,1989

4. Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by LC-MS/MS;Fan;Rheumatol Ther,2015

5. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial;Gautret;Int J Antimicrob Agents,2020

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of the SARS-CoV-2 Virus in Brain Cells;Viral Immunology;2024-03-01

2. The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel;AAPS PharmSciTech;2023-08-11

3. Early Treatment with Hydroxychloroquine and Azithromycin: A ‘Real-World’ Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients;2023-04-04

4. Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic;Brazilian Journal of Pharmaceutical Sciences;2023

5. The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling;Drug Metabolism and Personalized Therapy;2022-10-10